Home › Blog › Cardiology › AI Cardiology Accuracy

Quick Answer

Concordance data from 2024-26 shows AI chatbots perform respectably on structured cardiology guideline questions and fail predictably on complexity, currency, and jurisdiction. ChatGPT answered 2023 ESC acute coronary syndrome questions with 80 to 84 percent multiple-choice accuracy across repeat testing (Life, 2024), and a targeted review reported up to 86 percent concordance with expert decisions on ACS questions (Future Cardiol, 2025). The same model family scored 50 percent on adult congenital heart disease questions where subspecialists scored 87.5 percent. For Indian cardiologists two further gaps apply: models anchored to Western risk calculators inherit their documented underestimation of South Asian cardiovascular risk, and no general chatbot has been benchmarked against CSI or Lipid Association of India guidance.

Key Takeaways

• Structured guideline questions are the strong suit: 80 to 84 percent multiple-choice accuracy against 2023 ESC ACS guidance, with high 30-day consistency (kappa 0.93; Life, 2024), and median accuracy scores of 5.5 to 6 on a 6-point scale against the 2025 SCAI/HRS left atrial appendage occlusion guidelines (J Int Med Res, 2026).
• Complexity is the weak suit: ChatGPT-4 answered 50 percent of adult congenital heart disease questions correctly, against 87.5 percent for paediatric cardiologists and 68.8 percent for general cardiologists (Int J Cardiol Congenit Heart Dis, 2024).
• Currency is a structural problem in cardiology specifically. ESC Congress 2025 delivered a revised valvular heart disease guideline, a new combined myocarditis and pericarditis guideline, a revised cardiovascular disease in pregnancy guideline, and a focused dyslipidaemia update endorsing SCORE2 and SCORE2-OP.
• Risk estimation carries an inherited bias: the Pooled Cohort Equations failed to capture a greater than two-fold excess in observed atherosclerotic events among South Asians in UK Biobank and underestimated risk in low-risk South Asian categories in a Kaiser Permanente cohort.
• No published study has tested any general chatbot against the CSI dyslipidemia guidelines (2024) or Lipid Association of India consensus statements.

Why This Matters at the Indian Point of Care

India carries an epidemic of premature coronary artery disease; the CSI guidelines exist precisely because dyslipidemia patterns, onset age, and risk architecture in Indian patients differ from the cohorts behind ESC and ACC/AHA recommendations. Indian cardiologists and physicians managing cardiac patients already put guideline questions to general chatbots between patients: anticoagulation choices, heart failure sequencing, lipid targets, device eligibility. The published record now allows a precise answer to whether that habit is defensible, and the answer depends entirely on the type of question asked.

What Does the Concordance Evidence Show on AI Cardiology Accuracy?

Structured guideline questions: genuinely good. Geneş and Çelik put questions built from the 2023 ESC acute coronary syndrome guidelines to ChatGPT at 30-day intervals. Multiple-choice accuracy was 80 percent initially and 84 percent on retest, with near-perfect consistency between sittings (Cohen's kappa 0.93; Life, 2024). A 2026 study in the Journal of International Medical Research tested ChatGPT-5, ChatGPT-4o, DeepSeek-R1, and DeepSeek-V3 on clinical questions from the 2025 SCAI/HRS left atrial appendage occlusion guidelines: median accuracy scores ranged from 5 to 6 on a 6-point Likert scale, with ChatGPT-4o at the top. A targeted review of seven studies on LLMs and ESC guideline interpretation reported concordance with expert clinical decisions of up to 86 percent for ACS questions (Future Cardiol, 2025).

Heart failure management: usable with supervision. A 2026 study in Acta Cardiologica presented 38 anonymised heart failure vignettes spanning HFrEF, HFmrEF, and HFpEF phenotypes to ChatGPT-5, graded by two board-certified cardiologists against the 2023 ESC and 2022 ACC/AHA/HFSA recommendations. The design is the message: even favourable evaluations of the newest models are anchored to guideline versions that the ESC 2025 cycle is already revising around the edges, and graded by humans who know the difference.

Complexity: the documented ceiling. In adult congenital heart disease, ChatGPT-4 answered 50 percent of diagnostic questions correctly. Paediatric and ACHD cardiologists scored 87.5 and 83.3 percent; general cardiologists scored 68.8 percent. The model performed below every human comparator group. The pattern matches the OBGYN and oncology literature: accuracy collapses where questions require layered reasoning across anatomy, physiology, and prior interventions rather than retrieval of a single recommendation.

Consistency and the moderate-reliability caveat. The LAAO study found high reproducibility across repeated queries but only moderate inter-rater reliability among the cardiologist graders themselves, a reminder that concordance is difficult for everyone; the question is not whether AI is perfect but whether its failure modes are visible and correctable.

Where Generic AI Fails Indian Cardiologists Specifically

Guideline velocity. Cardiology revises faster than any specialty this series covers. ESC Congress 2025 in Madrid released four major documents in one week: the 2025 ESC/EACTS valvular heart disease guideline replacing 2021 guidance, the first combined ESC myocarditis and pericarditis guideline replacing the 2015 pericarditis document, a revised cardiovascular disease in pregnancy guideline replacing the 2018 version, and a focused update of the 2019 dyslipidaemia guidelines endorsing SCORE2 and SCORE2-OP for risk estimation (Eur Heart J, 2025). Every static-training chatbot in circulation on the morning of that congress became partially outdated by the evening.

Risk calculation for the wrong population. Western risk tools embedded in model training systematically misread Indian patients. In UK Biobank, South Asians experienced atherosclerotic cardiovascular events at 6.8 percent over follow-up against 4.4 percent for Europeans (HR 2.03), an excess the Pooled Cohort Equations did not capture. A Kaiser Permanente Northern California cohort found the PCE underestimated 10-year risk in South Asians classified as low risk: 4.9 percent observed against 1.8 percent predicted.

The Indian guideline layer is invisible. CSI published the first India-specific dyslipidemia guidelines in 2024 (Indian Heart Journal), built on ICMR-INDIAB epidemiology, recommending non-fasting lipid profiles and a first lipid screen at age 18. The Lipid Association of India consensus statement IV (J Clin Lipidol, 2024) adds India-specific risk stratification. No published concordance study has tested any chatbot against either document.

Access and formulary reality. Guideline-directed medical therapy questions have an availability dimension in India: generic sacubitril/valsartan and SGLT2 inhibitor pricing, PMJAY package coverage for interventions, device reimbursement. Western-trained models discuss list prices in dollars and insurance logic that does not map to an Indian cath lab's approval workflow.

Failure Modes at a Glance

What Actually Fixes This

The pattern across specialties is now consistent enough to state as a rule: model generations improve examination scores; retrieval architecture improves clinical reliability. The 2025 JAMIA meta-analysis across 20 studies found retrieval-augmented generation significantly improved accuracy over baseline LLMs (pooled OR 1.35; 95 percent CI 1.19-1.53). Guideline-as-context designs raised accuracy from 43 to 99 percent in a hepatology framework study. In cardiology specifically, the Future Cardiology review highlights tools built for direct ESC guideline interpretation as the feasible path.

Retrieval is also the only architecture that survives guideline velocity. A system that indexes the 2025 ESC/EACTS valvular document the week it publishes answers from it the same week; a static model waits for retraining. This is the design premise of OneRX, an AI clinical decision support platform for doctors: retrieval-grounded answers from current guidelines and primary literature, with CSI, LAI, and ICMR sources indexed alongside ESC and ACC/AHA, citations that resolve, and the decision left with the cardiologist.

Practical Guidance for Cardiologists Using General Chatbots Today

• Defensible: drafting patient explanations, summarising a trial publication you supply, structuring a differential for review, board-style self-testing on stable content.
• High-risk: any question touching guidance revised since the model's training data ends, risk estimates for Indian patients, anticoagulation and heart failure dosing decisions, and any answer whose citation you have not personally resolved.
• Operating rule: date every answer. If the tool cannot tell you which guideline version it is quoting, treat the answer as of unknown vintage.

Frequently Asked Questions

Is ChatGPT accurate for cardiology guideline questions?

On structured questions from a fixed guideline, accuracy is genuinely high: 80 to 84 percent on 2023 ESC ACS material and median scores of 5.5 to 6 out of 6 on the 2025 LAAO guidelines. Accuracy falls sharply on complex reasoning (50 percent in adult congenital heart disease) and on any guidance revised after training.

Which cardiology guidelines changed at ESC 2025?

Four major documents: the 2025 ESC/EACTS valvular heart disease guideline, the first combined myocarditis and pericarditis guideline, a revised cardiovascular disease in pregnancy guideline, and a focused dyslipidaemia update endorsing SCORE2 and SCORE2-OP. Static-training chatbots predating August 2025 quote the superseded versions.

Do AI risk estimates work for Indian patients?

Not reliably. General models default to Framingham or Pooled Cohort Equations, which underestimated South Asian risk in UK Biobank (HR 2.03 for observed excess events) and in low-risk categories of a large US South Asian cohort. CSI 2024 guidance and India-calibrated approaches are the appropriate reference, and general chatbots rarely surface them.

Has any chatbot been validated against CSI or LAI guidelines?

No published concordance study has benchmarked a general-purpose chatbot against the CSI 2024 dyslipidemia guidelines or the Lipid Association of India consensus statements as of August 2026. Every major evaluation uses ESC, ACC/AHA, or SCAI/HRS comparators.

Can AI decision support be used for heart failure drug sequencing?

Evaluations against 2023 ESC and 2022 ACC/AHA/HFSA recommendations show usable but imperfect concordance, graded under expert supervision. Sequencing decisions involve dated guidance, comorbidity trade-offs, and Indian formulary realities; verify against a current, cited source before changing therapy.

Conclusion

The cardiology concordance literature is the clearest in this series: general chatbots are competent examinees and unreliable registrars. They score 80-plus percent on structured questions from guidelines they were trained on, drop to coin-flip performance on subspecialty complexity, and cannot know about the four major guidelines ESC released in a single week of 2025. For Indian cardiologists the inherited risk-calculator bias and the invisibility of CSI and LAI guidance add failure modes no Western evaluation measures. Retrieval-grounded evidence platforms with Indian sources indexed address the documented gaps; everything else requires the cardiologist to verify vintage, jurisdiction, and citation by hand.